Summary of Pharma Partnerships, Licensing, Investments, M&A Deals and Trends July 2015 - ref #GB000025
Partnerships, Licensing, Investments and M&A Deals and Trends for July 2015 in Pharmaceuticals
GlobalData's “Partnerships, Licensing, Investments and M&A Deals and Trends for July 2015 in Pharmaceuticals” report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in July 2015. The report portrays detailed comparative data on the number of deals and their value in the last six months, subdivided by deal types, various therapy areas, and geographies. Additionally, the report provides information on the top financial advisory firms in the pharmaceuticals industry.
Data presented in this report is derived from GlobalData’s proprietary in-house Pharmaceuticals eTrack deals database and primary and secondary research.
Scope
- Analysis of the market trends for the pharmaceutical industry in the global arena.
- Review of deal trends in the cardiovascular, central nervous system, dermatology, ear nose throat disorders, gastrointestinal, genito urinary system and sex hormones, hematological disorders, hormonal disorders, immunology, infectious disease, male health, metabolic disorders, mouth and dental disorders, musculoskeletal, oncology, ophthalmology, respiratory, toxicology, and women's health segments.
- Analysis of partnerships, licensing, M&As, equity/debt offerings, private equity, and venture financing deals in the pharmaceutical industry.
- Analysis of therapy areas which are very active in terms of venture capital financing, partnerships, licensing agreements, equity/debt offerings, and M&As.
- Analysis of deals based on different payment modes, including upfront and milestone payments, primarily in partnerships and licensing agreements in the pharmaceutical industry.
- Analysis of partnership and licensing deals based on clinical stage of development of products.
- Summary of the pharmaceutical deals globally in the six months.
- Information on the top deals happened in the pharmaceutical industry.
- Geographies covered include – North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa.
- League tables of financial advisors in M&As and equity/debt offerings. This includes key advisors such as Morgan Stanley, Credit Suisse, and Goldman Sachs.
Reasons to buy
- Enhance your decision making capability in a more rapid and time sensitive manner.
- Find out the major deal performing segments for investments in your industry.
- Evaluate the types of companies which are entering into partnership or licensing agreements; divesting and acquiring assets.
- Identify companies that are aggressively looking to raise capital in the market
- Evaluate niche therapy areas that are receiving majority of the upfront and milestone payments in the pharmaceutical industry.
- Identify the key venture capitalists, who are financing the pharmaceutical and biotech companies.
- Evaluate the clinical development stages where majority of the partnerships and licensing agreements are happening.
- Do deals with an understanding of how competitors are financed, and the mergers and partnerships that have shaped the pharmaceutical industry.
- Identify growth segments and opportunities in each region within the industry.
- Look for key financial advisors where you are planning to raise capital from the market or for acquisitions within the industry.
Contents
1 Table of Contents 2
1.1 List of Tables 6
1.2 List of Figures 9
2 Pharmaceuticals & Healthcare, Global, Deal Summary 12
2.1 Pharmaceuticals & Healthcare, Global, Deal Analysis, July 2015 12
2.2 Pharmaceuticals & Healthcare, Global, Major Deals, July 2015 14
2.2.1 Teva Pharma to Acquire Generics Drug Business from Allergan for USD40.5 Billion 14
2.2.2 Celgene Acquires Receptos for USD7.2 Billion 15
2.2.3 Hikma Pharma to Acquire Roxane Labs and Boehringer Ingelheim Roxane from Boehringer Ingelheim Pharma 16
2.2.4 Regeneron Pharma Enters into Co-Development Agreement with Sanofi 17
2.2.5 Biogen Enters into Licensing Agreement with Applied Genetic Technologies 19
2.3 Pharmaceuticals & Healthcare, Global, by Type, Number of Deals, July 2015 20
2.4 Pharmaceuticals & Healthcare, Global, by Type, Deal Values, July 2015 21
3 Pharmaceuticals and Healthcare, Global, Deals, Summary, by Type 22
3.1 Pharmaceuticals & Healthcare, Global, M&A, July 2015 22
3.1.1 Top M&A Deals in July 2015 23
3.1.2 Pharmaceuticals & Healthcare, Global, M&A Deals by Therapy Area, February 2015 - July 2015 24
3.2 Pharmaceuticals & Healthcare, Global, Equity Offering Deals, July 2015 25
3.2.1 Top Equity Offering Deals in July 2015 26
3.2.2 Pharmaceuticals & Healthcare, Global, Equity Offering Deals by Therapy Area, February 2015 - July 2015 27
3.3 Pharmaceuticals & Healthcare, Global, Private Equity and Venture Capital Deals, July 2015 28
3.3.1 Top PE/VC Deals in July 2015 29
3.3.2 Pharmaceuticals & Healthcare, Global, PE/VC by Therapy Area, July 2015 30
3.3.3 Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, July 2015 31
3.3.4 Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, February 2015-July 2015 33
3.3.5 Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, February 2015-July 2015 34
4 Pharmaceuticals & Healthcare, Global, Partnership Deals, July 2015 35
4.1 Pharmaceuticals & Healthcare, Global, Partnership Deals, July 2015 35
4.2 Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, February 2015 - July 2015 37
4.3 Pharmaceuticals & Healthcare, Global, Partnership Deals by Upfront and Milestone Payments and Deal Values (US$ m), July 2015 38
4.3.1 Pharmaceuticals & Healthcare, Global, Top Partnership Deals by Payment Mode, July 2015 39
4.4 Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, by Upfront and Milestone Payments and Deal Values (US$ m), February 2015 - July 2015 40
4.5 Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, Number Of Deals, February 2015 - July 2015 42
4.6 Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, Deal Values (US$ m), February 2015 - July 2015 43
4.7 Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), February 2015 - July 2015 45
5 Pharmaceuticals & Healthcare, Global, Licensing Agreements, July 2015 47
5.1 Pharmaceuticals & Healthcare, Global, Licensing Agreements, July 2015 47
5.2 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Upfront and Milestone Payments and Deal Values (US$ m), July 2015 49
5.3 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Total Deal Values (US$ m), February 2015 - July 2015 51
5.4 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Upfront Payments and Milestone Payments (US$ m), February 2015 - July 2015 53
5.5 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Total Deal Values (US$ m), February 2015 - July 2015 55
5.6 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Upfront Payments and Milestone Payments (US$ m), February 2015 - July 2015 57
5.6.1 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements by Deal Value, July 2015 59
5.6.2 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Total Upfront Payments, July 2015 60
5.6.3 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements by Total Milestone Payment, July 2015 60
6 Pharmaceuticals & Healthcare, Global, Deal Summary by Therapy Area 61
6.1 Pharmaceuticals & Healthcare, Global, Oncology Deals, July 2015 61
6.1.1 Oncology - Deals of the Month 62
6.2 Pharmaceuticals & Healthcare, Global, Central Nervous System Deals, July 2015 66
6.2.1 Central Nervous System - Deals of the Month 67
6.3 Pharmaceuticals & Healthcare, Global, Infectious Disease Deals, July 2015 70
6.3.1 Infectious Diseases - Deals of the Month 71
6.4 Pharmaceuticals & Healthcare, Global, Cardiovascular Deals, July 2015 73
6.4.1 Cardiovascular - Deals of the Month 74
6.5 Pharmaceuticals & Healthcare, Global, Immunology Deals, July 2015 76
6.5.1 Immunology - Deals of the Month 77
6.6 Pharmaceuticals & Healthcare, Global, Respiratory Deals, July 2015 79
6.6.1 Respiratory - Deals of the Month 80
6.7 Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals, July 2015 82
6.7.1 Metabolic Disorders - Deals of the Month 83
7 Deal Summary by Geography 85
7.1 Pharmaceuticals & Healthcare, North America Deals, July 2015 85
7.1.1 North America - Deals of the Month 86
7.2 Pharmaceuticals & Healthcare, Europe, Deals, July 2015 88
7.2.1 Europe - Deals of the Month 89
7.3 Pharmaceuticals & Healthcare, Asia-Pacific, Regional Deals, July 2015 91
7.3.1 Asia-Pacific - Deals of the Month 92
7.4 Pharmaceuticals & Healthcare, Rest of the World, Deals, July 2015 93
7.4.1 ;Rest of the World - Deals of the Month 94
8 Pharmaceuticals & Healthcare, Global, Top Financial Advisors 95
8.1 Pharmaceuticals & Healthcare, Global, Top Financial Advisors, M&A, February 2015 - July 2015 95
8.2 Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, February 2015 - July 2015 97
9 Further Information 99
9.1 Methodology 99
9.2 About GlobalData 100
9.3 Disclosure information 100
9.4 Disclaimer 101
List of Tables
Table 1: Pharmaceuticals & Healthcare, Global, Deals Summary, Number of Deals and Deal Values (US$ m), February 2015 - July 2015 13
Table 2: Pharmaceuticals & Healthcare, Global, Major Deals, July 2015 14
Table 3: Pharmaceuticals & Healthcare, Global, Number Of Deals and Deal Values (%), July 2015 21
Table 4: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), February 2015 - July 2015 23
Table 5: Pharmaceuticals & Healthcare, Global, Top M&A Deals, July 2015 23
Table 6: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), by Therapy Area, February 2015 - July 2015 24
Table 7: Pharmaceuticals & Healthcare, Global, Equity Offerings, Deals Summary, Number of Deals and Deal Values (US$ m), February 2015 - July 2015 26
Table 8: Pharmaceuticals & Healthcare, Global, Top Equity Offering Deals, July 2015 26
Table 9: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Deals Summary, Number of Deals and Deal Values (US$ m), February 2015 - July 2015 27
Table 10: Pharmaceuticals & Healthcare, Global, PE/VC, Deals Summary, Number of Deals and Deal Values (US$ m), February 2015 - July 2015 29
Table 11: Pharmaceuticals & Healthcare, Global, Top PE/VC Deals, July 2015 29
Table 12: Pharmaceuticals & Healthcare, Global, PE/VC Deals by Therapy Area, Deals Summary, February 2015 - July 2015 30
Table 13: Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Number Of Deals and Deal Values (%), July 2015 32
Table 14: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), February 2015 - July 2015 33
Table 15: Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, February 2015 - July 2015 34
Table 16: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), February 2015 - July 2015 36
Table 17: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Number of Deals and Deal Values (US$ m), February 2015 - July 2015 37
Table 18: Pharmaceuticals & Healthcare, Partnership Deals, Upfront and Milestone Payments and Deal Values (US$ m), February 2015 - July 2015 38
Table 19: Pharmaceuticals & Healthcare, Global, Partnerships, Upfront and Milestone Payments and Deal Values (US$ m), July 2015 39
Table 20: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), February 2015 - July 2015 41
Table 21: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, February 2015 - July 2015 44
Table 22: Pharmaceuticals & Healthcare, Global, Partnership Deals by Upfront and Milestone Payment and Deal values (US$ m), February 2015 - July 2015 46
Table 23: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Deals Summary, Number of Deals and Deal Values (US$ m), February 2015 - July 2015 48
Table 24: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Deals Summary, Upfront and Milestone Payments and Deal Values (US$ m), February 2015 - July 2015 50
Table 25: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Number of Deals and Deal Values (US$ m), February 2015 - July 2015 52
Table 26: Pharmaceuticals & Healthcare, Global, Licensing Agreements by Therapy Area, by Upfront and Milestone Payments (US$ m), July 2015 54
Table 27: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, February 2015 - July 2015 56
Table 28: Pharmaceuticals & Healthcare, Global, Licensing Agreements by Therapy Area, by Upfront and Milestone Payments and Deal Values (US$ m), July 2015 58
Table 29: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Value, July 2015 59
Table 30: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Total Upfront Payments, July 2015 60
Table 31: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Total Milestone Payment, July 2015 60
Table 32: Pharmaceuticals & Healthcare, Global, Oncology, Deals Summary, Number of Deals and Deal Values (US$ m), February 2015 - July 2015 62
Table 33: Pharmaceuticals & Healthcare, Global, Central Nervous System, Deals Summary, Number of Deals and Deal Values (US$ m), February 2015 - July 2015 67
Table 34: Pharmaceuticals & Healthcare, Global, Infectious Diseases, Deals Summary, Number of Deals and Deal Values (US$ m), February 2015 - July 2015 71
Table 35: Pharmaceuticals & Healthcare, Global, Cardiovascular, Deals Summary, Number of Deals and Deal Values (US$ m), February 2015 - July 2015 74
Table 36: Pharmaceuticals & Healthcare, Global, Immunology, Deals Summary, Number of Deals and Deal Values (US$ m), February 2015 - July 2015 77
Table 37: Pharmaceuticals & Healthcare, Global, Respiratory, Deals Summary, Number of Deals and Deal Values (US$ m), February 2015 - July 2015 80
Table 38: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), February 2015 - July 2015 83
Table 39: Pharmaceuticals & Healthcare, North America, Deals Summary, Number of Deals and Deal Values (US$ m), February 2015 - July 2015 86
Table 40: Pharmaceuticals & Healthcare, Europe, Deals Summary, Number of Deals and Deal Values (US$ m), February 2015 - July 2015 89
Table 41: Pharmaceuticals & Healthcare, Asia-Pacific, Deals Summary, Number of Deals and Deal Values (US$ m), February 2015 - July 2015 92
Table 42: Pharmaceuticals & Healthcare, Rest of the World, Deals Summary, Number of Deals and Deal Values (US$ m), February 2015 - July 2015 94
Table 43: Pharmaceuticals & Healthcare, Top Financial Advisors, M&A, Number of Deals and Deal Values (US$ m), February 2015 - July 2015 96
Table 44: Pharmaceuticals & Healthcare, Global Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), February 2015 - July 2015 98
1.2 List of Figures
Figure 1: Pharmaceuticals & Healthcare, Global, Number of Deals and Deal Values (US$ m), February 2015 - July 2015 12
Figure 2: Pharmaceuticals & Healthcare, Global, Number Of Deals (%), July 2015 20
Figure 3: Pharmaceuticals & Healthcare, Global, Deal Values (%), July 2015 21
Figure 4: Pharmaceuticals & Healthcare, Global, M&As, Number of Deals and Deal Values (US$ m), February 2015 - July 2015 22
Figure 5: Pharmaceuticals & Healthcare, Global, M&As by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, February 2015 - July 2015 24
Figure 6: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Number of Deals and Deal Values (US$ m), February 2015 - July 2015 25
Figure 7: Pharmaceuticals & Healthcare, Global, Equity Offering Deals by Therapy Area, Number of Deals and Deal Values (US$ m), February 2015 - July 2015 27
Figure 8: Pharmaceuticals & Healthcare, Global, Private Equity and Venture Capital, Number of Deals and Deal Values (US$ m), February 2015 - July 2015 28
Figure 9: Pharmaceuticals & Healthcare, Global, PE/VC Deals by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, February 2015 - July 2015 30
Figure 10: Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Number Of Deals (%), July 2015 31
Figure 11: Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Deal Values (%), July 2015 32
Figure 12: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), February 2015 - July 2015 33
Figure 13: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), February 2015 - July 2015 35
Figure 14: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Number of Deals and Deal Values (US$ m), February 2015 - July 2015 37
Figure 15: Pharmaceuticals & Healthcare, Global, Partnership Deals, Upfront and Milestone Payments and Deal Values (US$ m), February 2015 - July 2015 38
Figure 16:Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), February 2015 - July 2015 40
Figure 17: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, February 2015 - July 2015 42
Figure 18: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, February 2015 - July 2015 43
Figure 19:Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), February 2015 - July 2015 45
Figure 20:Pharmaceuticals & Healthcare, Global, Licensing Agreements, Number of Deals and Deal Values (US$ m), February 2015 - July 2015 47
Figure 21:Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Upfront and Milestone Payments and Deal Values (US$ m), February 2015 - July 2015 49
Figure 22:Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Number of Deals and Deal Values (US$ m), February 2015 - July 2015 51
Figure 23:Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), February 2015 - July 2015 53
Figure 24: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Number Of Deals, February 2015 - July 2015 55
Figure 25: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Deal Values (US$ m), February 2015 - July 2015 56
Figure 26:Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, by Upfront and Milestone Payments and Deal Values (US$ m), July 2015 57
Figure 27: Pharmaceuticals & Healthcare, Global, Oncology, Number of Deals and Deal Values (US$ m), February 2015 - July 2015 61
Figure 28: Pharmaceuticals & Healthcare, Global, Central Nervous System, Number of Deals and Deal Values (US$ m), February 2015 - July 2015 66
Figure 29: Pharmaceuticals & Healthcare, Global, Infectious Diseases, Number of Deals and Deal Values (US$ m), February 2015 - July 2015 70
Figure 30: Pharmaceuticals & Healthcare, Global, Cardiovascular, Number of Deals and Deal Values (US$ m), February 2015 - July 2015 73
Figure 31: Pharmaceuticals & Healthcare, Global, Immunology, Number of Deals and Deal Values (US$ m), February 2015 - July 2015 76
Figure 32: Pharmaceuticals & Healthcare, Global, Respiratory, Deals Summary, Number of Deals and Deal Values (US$ m), February 2015 - July 2015 79
Figure 33: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), February 2015 - July 2015 82
Figure 34: Pharmaceuticals & Healthcare, North America, Number of Deals and Deal Values (US$ m), February 2015 - July 2015 85
Figure 35: Pharmaceuticals & Healthcare, Europe, Number of Deals and Deal Values (US$ m), February 2015 - July 2015 88
Figure 36: Pharmaceuticals & Healthcare, Asia-Pacific, Number of Deals and Deal Values (US$ m), February 2015 - July 2015 91
Figure 37: Pharmaceuticals & Healthcare, Rest of the World, Number of Deals and Deal Values (US$ m), February 2015 - July 2015 93
Figure 38: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, M&A, Number of Deals and Deal Values (US$ m), February 2015 - July 2015 95
Figure 39: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), February 2015 - July 2015 97
Publisher: GlobalData
Date of publication: September 2015
Terms and Conditions
GLOBALDATA TERMS AND CONDITIONS
Single Copy Report Products
GlobalData Ltd (“Holding Company”), a company registered in England with the company number 05968121 and registered office at John Carpenter House, John Carpenter Street, London, EC4Y 0AN, United Kingdom. These terms and conditions and the Order Form comprise the agreement pursuant to which Company provides the Product (defined below) to you ("Agreement"). "We", "us", "our" or “GlobalData” refers to Company. "You" or "your" refers to the person who (or on whose behalf) an Order is placed and includes your legal successors and permitted assigns.
1. Order Forms: Order Forms shall only be binding when accepted by us. You shall not cancel or amend an Order Form unless we have given our prior written consent. We shall assume that any person who places an Order Form on your behalf can bind you legally.
2. Ownership: The legal and beneficial interest in all copyrights, patents, trade marks, service marks, design rights (whether registered or unregistered), database rights, proprietary information rights and all other proprietary rights as may exist anywhere in the world together with applications associated with any such rights ("Intellectual Property Rights") relating to the Product belong to us, the holding company, or our licensors, as the case may be, at all times. You obtain no ownership rights in the Product or any of the Intellectual Property Rights pursuant to or arising out of this Agreement.
3. Grant of License: We grant you a non exclusive, non transferable license to use the products described in the Order Form ("Product"). You warrant that you shall only use the Product for your business purposes in accordance with this agreement and shall not, without our prior written consent, make available, copy, reproduce, retransmit, disseminate, sell, license, distribute, publish, broadcast or otherwise circulate the Product (or any part of it) to any person other than in accordance with these terms and conditions. You further warrant that you shall comply with all applicable laws and regulations and shall not knowingly use the Product for any improper or unlawful purposes.
4. License: Unless stated otherwise on the Order Form the Product is licensed to you on a single user basis. Only the user named on the Order Form as the customer may use the product as outlined in this agreement. Additional user licenses may be purchased by you at our prevailing standard list prices for single users or by the purchase of a site wide or enterprise wide license. You warrant that you will use appropriate controls to ensure that the license is not breached by you or by other users and agree that any breach may cause us irrepreable harm. You agree we have the right to charge additional fees for unauthorized usage in line with our standard list prices. This clause survives termination of the Agreement.
5. Fees and Payment Terms: Payment is due in full prior to delivery of any product. We shall invoice you for fees payable by you to us under this Agreement ("Fees") upon our acceptance of an Order Form. Unless indicated otherwise on the Order Form you will pay all invoices on receipt of that invoice. We may issue the invoice in print and/or electronic form. Unless expressly provided the fees exclude any sales, use, excise, or other applicable taxes. You will pay or reimburse us for any such taxes for which either party may become held responsible for. A fee for late payment will be assessed equal to the lower of one and one half percent (1.5%) per month and the maximum permitted by law. In addition you agree that all sales are final and that you may not request a refund. We reserve the right, for any reason whatsoever, to withold delivery of the Product to you until payment has been received in full.
6. Warranties: We shall use best endeavors to ensure the Product is provided to you in accordance with any specifications set out in the Order Form and accepted by us. We do not warrant that the Product will meet your requirements or that it will be complete, error free or delivered without interruption. Findings, conclusions and recommendations in the Product are based on information gathered in good faith from both primary and secondary sources, whose accuracy we are not always in a position to guarantee. As such, we can accept no liability whatsoever for actions taken based on any information that may subsequently prove to be incorrect. Except as expressly set out in this Agreement, all express or implied representations, warranties, conditions and undertakings are excluded to the maximum extent permissible by law. You assume sole responsibility for the selection, suitability and use of the Product and acknowledge that except as stated above we do not provide any additional warranties or guarantees relating to the Product. This clause survives termination of the Agreement.
7. Indemnification. Generally. We and You (“Both Parties”) will, to the extent permitted by law, indemnify, defend and hold harmless the other party from and against any and all claims, demands, complaints, or actions of third parties (including employees of the parties) arising from or relating to this agreement, including personal injury, death and property damage to the extent caused or arising out of the violation of law, gross negligence, fraud, willful misconduct or breach of this agreement. In the event that both parties are at fault they will indemnify each other in proportion to their relative negligence. In addition we will indemnify, defend and hold harmless, you from and against any and all claims, demands, complaints or actions of third parties (including employees of the parties) arising from or relating to this agreement brought against you alleging that the product infringe any patent, copyright, trademark, trade secret or other intellectual property right. Our obligations under this section are conditioned on you i) Promptly notifying us of any claim, ii) Granting us sole control over the defense and settlement of the action. iii) Reasonably cooperating with us in connection with such action at our expense, iv) Abetting no such claim, demand, complaint or action v) Neither modifying or using the product nor breaching this agreement in a manner for which no infringement would have occurred. If the product becomes or in our opinion is likely to become the subject of such a claim, then in lieu of the indemnity we may, at our expense, i) procure you the right to license using or receiving the product free of any such liability, ii) replace or modify in whole or part the product to make them non-infringing without degradation or iii) refund you a pro-rata portion of the fee.
8. Limitation of liability: Neither party shall be liable under this agreement to the other party for indirect, special, exemplary, punitive or consequential damages including without limitation loss of goodwill, whether arising from negligence, breach of contract or otherwise. Our liability in contract, tort or otherwise arising out of or in connection with the Agreement shall in respect of any one or more incidents not exceed the total fees received by us from you for the Product in the 12 months prior to the date the incident occurs. This clause shall survive termination of the Agreement.
9. Confidentiality: Neither party shall, except as required to perform our and / or your respective rights and obligations, use, copy, adapt, alter, disclose to any third party or part with possession of any information or data of the other party which is disclosed or otherwise comes into our or your possession directly or indirectly as a result of these Terms and which is of a confidential nature, in writing marked confidential or, if disclosed orally, reduced to writing and marked confidential within 30 days of the date of such disclosure ("Information"). This obligation shall not apply to Information:
a. the receiving party can prove was in its possession at the date it was received or obtained; or
b. the receiving party obtains from some person other than us, you or an Affiliate with good legal title thereto; or
c. comes into the public domain otherwise than through the default or negligence of the receiving party; or
d. is independently developed by or for the receiving party.
10. Solicitation. You agree that for a period of twelve (12) months immediately following the delivery of the products purchased, for any reason, whether with or without cause, you shall not either directly or indirectly solicit, induce, recruit or encourage any of the Company’s employees, who were involved in the sale, marketing, support or production of the product used, to leave their employment, or attempt to solicit, induce, recruit, encourage or take away employees of the Company.
11. Force Majeure: We shall not be liable for any delay or failure to perform any obligation under this Agreement insofar as the performance of such obligation is prevented by an event beyond our reasonable control, including but not limited to, earthquake, fire, flood or any other natural disaster, labor dispute, riot, revolution, terrorism, acts of restraint of government or regulatory authorities, failure of computer equipment and failure or delay of sources from which data is obtained.
12. Further Provisions: The Agreement constitutes the entire understanding between the parties relating to the Product and supersedes all previous agreements and understandings whether oral or written relating to the Product. In the event of any inconsistency between these terms and conditions and the Order, the Order shall prevail. The Agreement may only be varied in writing signed by an authorized representative of each party. Failure at any time to enforce any of these terms and conditions or to require performance by the other party of any such term or condition shall not be construed as a waiver of such provision or affect the right of either party to enforce the same. If any provision is held to be invalid or unenforceable by any tribunal of competent jurisdiction, the remaining provisions shall not be affected and shall be carried out as closely as possible according to the original intent. The Agreement does not confer any rights to or on any third party. The Agreement shall be governed by the laws of England and Wales. The parties irrevocably agree to the exclusive jurisdiction of the Courts of England.
Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches
